Protalix BioTherapeutics PLX is set to give its latest quarterly earnings report on Monday, 2023-08-07. Here's what investors need to know before the announcement.
Analysts estimate that Protalix BioTherapeutics will report an earnings per share (EPS) of $-0.04.
Protalix BioTherapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at Protalix BioTherapeutics's past performance and the resulting price change:
| Quarter | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.15 | -0.15 | -0.18 | |
| EPS Actual | -0.05 | -0.07 | -0.07 | -0.11 |
| Price Change % | -2.68% | 3.74% | 0.0% | 0.0% |
Stock Performance
Shares of Protalix BioTherapeutics were trading at $1.72 as of August 03. Over the last 52-week period, shares are up 51.62%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
